List view / Grid view
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
RM radiation doses were significantly higher in the patients who did not receive predosing, indicating that pre-dosing with lilotomab has a protective...
5 September 2016 | By Biopharma Group
Fluid processing requirements are becoming ever more stringent, and so high pressure homogenisation is increasingly surfacing as a solution to meeting these needs...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two…
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The approval is based on data from the phase 3b clinical trial, which examined the efficacy and safety of liraglutide versus placebo as an add-on to existing diabetes medication, to improve glycaemic control...
2 September 2016 | By CI Precision
Aesica Pharmaceuticals is implementing CI Precision’s MES solution (Ci-DMS) in their dispensing areas to remove labour-intensive manual processes, improve data integrity and integrate with their SAP ERP system.
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer...
2 September 2016 | By PerkinElmer Inc
ChemDraw software moves to the cloud for enhanced collaboration among chemists and biologists...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events…
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The drug exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC and met its primary endpoint of ORR. Tumours were tested for ROS1 rearrangements by laboratory-developed break-apart fluorescence in situ hybridization (FISH) (96%) or real-time polymerase chain reaction (RT-PCR) (4%) assay...
31 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL...
Market leaders in temperature controlled microscopy, Linkam Scientific Instruments, in response to user input have released new system control and imaging processing software - LINK...
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261)...
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The trial showed adding praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline, compared to 2% increase for placebo...
30 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA have granted Santhera an award of $246,000 in support of its ongoing Phase I trial with omigapil (callisto) incongenital muscular dystrophy (CMD)...
